Interestingly, serine phosphatase PP2A-activating drugs were recently found to kill therapy-resistant chronic myeloid leukemia (CML) stem cells [16]. This evidence concerns the gene PTPA and chronic myelogenous leukemia, BCR-ABL1 positive.